Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1516-1521

  Li, Xiao ^a   Chang, Chunkang ^a   He, Qi ^a   Xu, Feng ^a   Zhang, Qingxia ^a   Wu, Lingyun ^a   Su, Jiying ^a   Zhang, Xi ^a   Zhou, Liyu ^a   Wu, Dong ^a   Song, Luxi ^a   Zhang, Zheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Decitabine; FISH; Minimal residual disease; Myelodysplastic syndrome; Revised IPSS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CLONE; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME G BAND; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE;

DECITABINE; FISH; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; REVISED IPSS;

ABNORMAL KARYOTYPE; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM, RESIDUAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84886782202     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.09.006     Document Type: Article

References (24)

1. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72:141-196.
2. Herman J.G. Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 1999, 9:359-367.
3. Mund C., Hackanson B., Stresemann C., Lübbert M., Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005, 65:7086-7090.
4. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
5. Yang A.S., Doshi K.D., Choi S.W., Mason J.B., Mannari R.K., Gharybian V., et al. DNA methylation changes after 5-Aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006, 66:5495-5503.
6. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
7. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
8. Steensma D.P., Baer M.R., Slack J.L., Buckstein R., Godley L.A., Garcia-Manero G., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27:3842-3848.
9. Lee J.H., Jang J.H., Park J., Park S., Joo Y.D., Kim Y.K., et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica 2011, 96:1441-1447.
10. Iastrebner M., Jang J.H., Nucifora E., Kim K., Sackmann F., Kim D.H., et al. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. Leuk Lymphoma 2010, 51:2250-2257.
11. Bello C., Yu D., Komrokji R.S., Zhu W., Wetzstein G.A., List A.F., et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011, 117:1463-1469.
12. Balleisen S., Kuendgen A., Hildebrandt B., Haas R., Germing U. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. Leuk Res 2009, 33:1189-1193.
13. Wu L., Li X., Su J., He Q., Zhang X., Chang C., et al. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. J Cancer Res Clin Oncol 2011, 137:1563-1569.
14. Lübbert M., Wijermans P., Kunzmann R., Verhoef G., Bosly A., Ravoet C., et al. Cytogenetic responses in high risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2-deoxycytidine. Br J Haematol 2001, 114:349-357.
15. Rüter B., Wijermans P., Claus R., Kunzmann R., Lübbert M. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 2007, 110:1080-1082.
16. Kantarjian H., Huang X., Issa J.P. Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule. Blood 2007, 110:1083.
17. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Solé F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
18. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
19. Bennett J.M., Catovsky D., Daniel M.T. Proposals for the classification of the acute leukaemias: French-American-British cooperative group. Br J Haematol 1976, 33:451-458.
20. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
21. Shaffer L.G., Tommerup N. ISCN 2005 An International System for Human Cytogenetic Nomenclature 2005, S. Karger, Basel, Switzerland.
22. Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
23. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
24. Li X., Wu L., Ying S., Chang C., He Q., Pu Q. Differentiation and hematopoietic-support of clonal cells in myelodysplastic syndromes. Leuk Lymphoma 2007, 48:1353-1371.